Glycine for Sleep and Relaxation
Glycine sits at the intersection of two distinct nervous-system effects that both translate into better sleep. As a direct inhibitory neurotransmitter at brainstem and spinal-cord receptors, it lowers neural excitability much like the body's own benzodiazepine. As a peripheral vasodilator, 3 g of oral glycine at bedtime lowers core body temperature by roughly 0.2–0.4 °C — the same physiological cue the brain reads as a sleep signal at dusk. The Bannai and Kawai randomized trials at the Ajinomoto laboratories in Tokyo, published 2007–2012, demonstrated that 3 g of glycine ingested 30–60 minutes before bed shortens sleep onset latency, increases slow-wave sleep, reduces next-day fatigue ratings, and improves cognitive performance on the day after a partial sleep restriction protocol. Unlike sedative-hypnotics, glycine has no documented next-day cognitive impairment, no withdrawal syndrome, no tolerance, and an exceptional safety profile across more than a century of human use.
Table of Contents
- The Two Mechanisms in Brief
- Glycine as an Inhibitory Neurotransmitter
- Thermoregulation: Cutaneous Vasodilation and Core-Temperature Drop
- The Bannai and Inagawa Sleep Trials (3 g Before Bed)
- Effects on Sleep Architecture and Slow-Wave Sleep
- NMDA Coagonism and the Suprachiasmatic Nucleus
- Daytime Calm, Anxiety, and Schizophrenia Research
- Dose, Form, and Timing
- Glycine in Sleep Stacks (Magnesium, GABA, L-Theanine)
- Cautions, Drug Interactions, and Who Should Avoid It
- Key Research Papers
- Connections
The Two Mechanisms in Brief
Most natural sleep aids work through one mechanism — melatonin signals time-of-day; magnesium relaxes muscle; L-theanine modulates GABA tone. Glycine is unusual because it acts through two essentially independent pathways that converge on the same outcome.
The first is direct neural inhibition. Glycine is the dominant inhibitory neurotransmitter in the brainstem and spinal cord, where it opens chloride channels on neurons and hyperpolarizes them — identical in effect to GABA in the higher brain. This reduces motor tone, dampens spinal reflexes, and quiets the network of brainstem nuclei that drive arousal during wakefulness.
The second is thermoregulatory. Oral glycine produces peripheral vasodilation through a mechanism that appears to involve NMDA receptor signaling in the suprachiasmatic nucleus of the hypothalamus — the brain's master circadian clock. Cutaneous vasodilation increases heat loss through the hands and feet, which in turn produces a measurable drop in core body temperature. The brain reads that core-temperature drop as a sleep-onset signal, the same signal it normally reads from the body's own circadian temperature curve at dusk.
These two effects compound. The neural inhibition reduces the chatter of arousal that keeps anxious or stressed people awake. The thermoregulatory cue tells the brain that biological sleep time has arrived. The result is a faster sleep onset and a deeper, more consolidated sleep architecture — without the receptor-occupation hangover of pharmaceutical hypnotics.
Glycine as an Inhibitory Neurotransmitter
The glycine receptor (GlyR) is a pentameric ligand-gated chloride channel structurally homologous to the GABAA receptor. When glycine binds, the channel opens and chloride ions flow into the neuron, hyperpolarizing its membrane and reducing its likelihood of firing an action potential. This is the textbook mechanism of fast inhibitory neurotransmission.
Glycine receptors are expressed most densely in the brainstem (reticular formation, raphe nuclei, motor nuclei of cranial nerves) and the spinal cord (motor neurons, interneurons of the dorsal horn). They are also present in lower density throughout the cerebellum, retina, and certain forebrain regions. The classic pharmacological probe of glycine receptor function is strychnine, which is a selective glycine receptor antagonist; strychnine poisoning produces the explosive hyperreflexia and tonic-clonic spasms that result when glycinergic inhibition is removed from the motor system.
For the sleep effect, the glycinergic neurons of the lateral and ventral medullary reticular formation are particularly important. These cells project to spinal motor neurons and produce the active inhibition of skeletal muscle that characterizes REM-sleep atonia — the protective paralysis that prevents sleepers from physically acting out their dreams. Loss of glycinergic REM-atonia, due to brainstem injury or to disorders such as REM-sleep behavior disorder, produces the dramatic flailing and shouting episodes seen in that condition.
Oral glycine raises plasma glycine, which raises cerebrospinal fluid glycine, which enhances signaling at brainstem and spinal glycine receptors. The net effect is a modest but real increase in baseline inhibitory tone — the molecular equivalent of turning down the brain's background gain. For chronically wired, ruminative, or anxious sleepers, that subtle reduction in arousal is often what unlocks faster sleep onset.
Thermoregulation: Cutaneous Vasodilation and Core-Temperature Drop
Core body temperature normally falls by approximately 0.5–1.0 °C across the sleep-onset transition. This temperature drop is not a passive consequence of lying down — it is an actively orchestrated thermoregulatory event driven by cutaneous vasodilation, particularly at the distal extremities (hands and feet), which dramatically increases heat loss to the environment. Sleep researchers have shown that the magnitude of distal skin vasodilation in the 30 minutes before lights-out predicts how quickly a person actually falls asleep.
The Kawai laboratory at the Ajinomoto Innovation Institute, working with collaborators at Jikei University School of Medicine, identified glycine's thermoregulatory mechanism in a series of experiments published from 2008 to 2015. Oral glycine administered to rats produced:
- A measurable increase in cutaneous (paw) blood flow within 30 minutes
- A corresponding decrease in core body temperature of approximately 0.5 °C
- A shortened latency to non-REM sleep onset
- An increase in time spent in non-REM sleep across the first sleep cycle
The vasodilation appears to be mediated centrally rather than at the peripheral vascular wall. Microinjection of glycine into the suprachiasmatic nucleus of the hypothalamus reproduces the peripheral vasodilation, and lesions of the suprachiasmatic nucleus abolish the effect. The current model is that glycine acts as an NMDA-receptor coagonist on suprachiasmatic neurons, which in turn signal downstream to the sympathetic outflow that controls cutaneous vasculature.
In humans, the equivalent measurement is the distal-to-proximal skin temperature gradient (DPG) — the difference between hand or foot temperature and chest temperature. Higher DPG (warmer extremities relative to the core) means more heat loss is occurring, and predicts faster sleep onset. Polysomnography studies of glycine in humans have documented increased DPG in the half-hour after a 3 g oral dose, paralleling the rat data.
The Bannai and Inagawa Sleep Trials (3 g Before Bed)
The clinical translation of the thermoregulatory data was led by Makoto Bannai and Kentaro Inagawa at Ajinomoto, working with several Japanese university partners. Their key trials are still the most rigorous human evidence on the sleep effects of glycine, and they established the conventional 3 g bedtime dose that is now standard in the sleep-supplement literature.
Bannai et al. 2007 (open-label). 19 adults with sleep complaints received 3 g of glycine 30 minutes before bed for several nights. The Pittsburgh Sleep Quality Index improved, daytime fatigue scores dropped, and subjective sleep satisfaction rose. This was a small uncontrolled study but established proof of concept.
Inagawa et al. 2006 (double-blind crossover). Healthy adults volunteering for a partial sleep-restriction protocol (sleep limited to 5.5 hours per night for three consecutive nights) received either 3 g of glycine or placebo before bed. The glycine arm showed:
- Reduced subjective fatigue and sleepiness in the morning
- Better performance on the Wilkinson Auditory Vigilance Test the next day
- Lower self-rated sleepiness on the Stanford Sleep Scale
The interpretation: even when total sleep time is held constant, glycine improves sleep quality enough to partially compensate for restriction.
Yamadera et al. 2007 (polysomnography). 7 adults with mild insomnia underwent polysomnography after 3 g of glycine vs. placebo. Glycine reduced sleep onset latency, increased the time spent in slow-wave sleep (the deepest stage 3 NREM sleep), and shifted the proportion of the night spent in deeper rather than lighter sleep stages. There was no suppression of REM sleep, which is a common adverse effect of pharmaceutical hypnotics.
Bannai et al. 2012 (Frontiers in Neurology). The Ajinomoto group's comprehensive review of their own and other glycine sleep data, presenting the integrated thermoregulatory mechanism and the case for glycine as a "sleep-improving amino acid" with a different pharmacology than benzodiazepines or melatonin.
The trials are small by modern standards and almost all were conducted by a single research group with a corporate interest in the outcome (Ajinomoto is the world's largest manufacturer of amino acids). Independent replication has been limited but generally supportive. The combination of small effect size, plausible mechanism, and exceptional safety has been enough to drive widespread adoption in the sleep-supplement market.
Effects on Sleep Architecture and Slow-Wave Sleep
Healthy sleep is not a uniform state — it is a cycle of distinct stages with characteristic EEG signatures. Stage 1 (light, drowsy sleep), stage 2 (sleep spindles and K-complexes), stage 3 (slow-wave sleep, also called deep sleep), and REM (rapid-eye-movement, dreaming sleep) cycle every 90 minutes or so through the night.
The most physiologically restorative stage is slow-wave sleep (SWS), characterized by large-amplitude delta waves on EEG. SWS is when growth-hormone release peaks, when glymphatic clearance of amyloid-beta and other waste products from the brain is most active, when the hippocampus consolidates declarative memories from the day, and when most physical recovery occurs. SWS proportion declines steeply with age — older adults can have 50–80% less SWS than they did in their 20s, which is one reason older adults wake feeling less refreshed.
The Yamadera polysomnography data and several smaller follow-up studies show that glycine modestly increases the proportion of the night spent in slow-wave sleep, particularly in the first sleep cycle (the first 90 minutes after sleep onset, when SWS is most prominent in young healthy sleepers). The effect is small but consistent — on the order of a 5–15% increase in SWS time, which is comparable to what is seen with low-dose melatonin or with strict sleep-hygiene interventions.
Importantly, glycine does not suppress REM sleep. Many pharmaceutical hypnotics (benzodiazepines, "Z-drugs" like zolpidem, certain antidepressants used for sleep) reduce REM, which over weeks of use produces a REM-rebound phenomenon when the drug is discontinued and may contribute to the cognitive effects of long-term use. Glycine's neutral effect on REM is part of its favorable profile.
NMDA Coagonism and the Suprachiasmatic Nucleus
The thermoregulatory mechanism above runs through NMDA glutamate receptors in the suprachiasmatic nucleus (SCN), the brain's master circadian pacemaker. NMDA receptors require two agonists to open — glutamate at the conventional ligand-binding site, and either glycine or D-serine at a separate "glycine site." Without the coagonist, the receptor cannot open even in the presence of glutamate.
The glycine site on the NMDA receptor is normally about 50% saturated under physiological conditions, which means modest increases in extracellular glycine produce modest increases in NMDA receptor function. In the SCN, this enhanced NMDA signaling appears to drive the downstream vasodilation that produces the core-temperature drop discussed above.
The NMDA-coagonist role is also the mechanism behind the schizophrenia research described in a later section — cortical NMDA hypofunction is thought to contribute to negative symptoms of schizophrenia, and high-dose glycine augments NMDA signaling in cortex as well as in SCN.
For sleep specifically, the NMDA coagonism is part of a feedback loop. Excessive NMDA stimulation drives arousal and excitotoxicity. Modest, well-timed NMDA stimulation in the SCN drives the appropriate circadian signal. The pharmacology is dose- and timing-dependent — this is why the optimal glycine sleep dose has converged on roughly 3 g (enough to enhance signal but not enough to over-drive cortical NMDA function), taken 30–60 minutes before bed (long enough to reach peak plasma levels at the moment of sleep onset).
Daytime Calm, Anxiety, and Schizophrenia Research
Glycine's inhibitory effects on the brainstem and its NMDA coagonism in cortex extend to anxiety and other daytime states beyond just sleep. Anecdotally, many users of bedtime glycine report a subjective sense of calm that begins within 30–60 minutes of dosing and persists into the next morning. Controlled trials of glycine specifically for anxiety in healthy adults are limited, but several mechanism-based observations support the calming effect:
- Glycine receptor agonism dampens neural excitability in brainstem arousal pathways
- NMDA receptor modulation is a target of several anxiolytic drug classes
- Adequate glycine supports glutathione synthesis (see the Glutathione Synthesis page), which reduces oxidative stress — a documented contributor to chronic anxiety states
The most extensive psychiatric trial data on glycine come from schizophrenia, where the rationale is enhancement of cortical NMDA receptor function to address the negative-symptom cluster (social withdrawal, blunted affect, alogia, anhedonia, cognitive deficits) that responds poorly to dopamine-blocking antipsychotics. High-dose glycine adjunctive trials (0.4–0.8 g/kg body weight, which translates to 30–60 g per day for a 75 kg adult) have demonstrated modest but reproducible improvements in negative symptoms when added to standard antipsychotic regimens. The CONSIST trial (Buchanan et al. 2007) was the largest single trial and showed smaller effects than the earlier Heresco-Levy work, but several meta-analyses support a real signal.
The schizophrenia doses are far above the sleep dose. Note that high-dose glycine is contraindicated in patients taking the antipsychotic clozapine — the only documented drug interaction of clinical importance, discussed in the cautions section below.
Dose, Form, and Timing
The conventional sleep dose is 3 g of glycine taken 30 to 60 minutes before bedtime. This dose was established empirically in the Bannai/Inagawa trials and has been the standard ever since. Some users find 2 g sufficient; others need 4–5 g for noticeable effect. There is no documented benefit to doses above 5 g for sleep purposes specifically.
Form considerations:
- Free-form glycine powder. The cheapest, fastest-absorbed, and most commonly used form. Pharmaceutical-grade glycine is sweet-tasting (about 0.7× the sweetness of sucrose) and dissolves rapidly in water. A flat 3 g (roughly 1 teaspoon) in 4–6 oz of room-temperature water 30 minutes before bed is the standard.
- Glycine capsules. Typically 500 mg or 1 g per capsule. 3–6 capsules of the standard dose. Slower absorption than powder due to capsule dissolution time, but more convenient for travel.
- Magnesium glycinate. A chelated form of magnesium where each magnesium ion is bound to two glycine molecules. Common as a magnesium supplement, but the glycine content (typically 100–200 mg per 1 g of magnesium glycinate) is below the threshold for direct sleep effects. The sleep benefit attributed to magnesium glycinate is mostly from the magnesium.
- Bone broth and gelatin. A 250 mL cup of well-prepared bone broth delivers 2–4 g of glycine plus a broader collagen amino-acid profile (proline, hydroxyproline). Works for sleep but the warm-fluid effect and the slower absorption from a food matrix make it less acutely effective than free-form powder.
- Collagen peptides. About 33% glycine by weight, so 10 g of collagen peptides delivers ~3.3 g of glycine. Same caveat as bone broth — slower absorption, but useful if you are already taking collagen for skin or joint reasons.
Timing considerations. Plasma glycine peaks roughly 30–60 minutes after an oral dose. The thermoregulatory drop in core body temperature follows by another 30–60 minutes. The ideal timing therefore is 30–60 minutes before intended sleep onset, not at the moment of lying down. Taking glycine at midnight when waking from a 2 a.m. awakening is generally too late — the thermoregulatory window has passed.
Glycine in Sleep Stacks (Magnesium, GABA, L-Theanine)
Glycine combines reasonably with most other natural sleep supports, because its mechanisms are largely independent. The most commonly combined agents:
- Magnesium (glycinate, threonate, or citrate) — magnesium is a cofactor for NMDA-receptor modulation, blocks the NMDA channel at rest, and is essential for melatonin synthesis. Magnesium deficiency is associated with poor sleep. The combination of 300–400 mg elemental magnesium + 3 g glycine at bedtime is a common, well-tolerated stack.
- L-Theanine — the calming amino acid from green tea, acts on GABA and modestly on AMPA/NMDA. 200–400 mg of L-theanine + 3 g glycine produces a synergistic calming effect that some users describe as more reliable than either alone.
- Melatonin (low dose, 0.3–1 mg) — melatonin signals biological night to the suprachiasmatic nucleus; glycine produces the thermoregulatory effect that follows the SCN's signal. The two are mechanistically complementary. Low-dose melatonin (under 1 mg) is generally preferred to the typical 3–10 mg over-the-counter doses, which produce supraphysiologic plasma levels and may disrupt rather than support natural rhythm.
- GABA — oral GABA absorption and central-nervous-system penetration are debated, but for users who report subjective benefit, GABA + glycine is a reasonable combination since the two activate the same chloride-channel family but in different anatomical regions.
- Glycine + apigenin/chamomile — the flavonoid apigenin binds benzodiazepine sites on GABAA receptors. Adds a complementary inhibitory tone in cortex on top of glycine's brainstem-and-spinal effect.
Combinations to avoid include prescription benzodiazepines and Z-drugs in the early phase of weaning — not because of toxicity, but because the deep additive sedation can be more than expected. Discuss any sleep-supplement combination with a clinician if you are tapering off prescription hypnotics.
Cautions, Drug Interactions, and Who Should Avoid It
- Clozapine interaction. The most clinically important caution. Glycine antagonizes the antipsychotic effect of clozapine and may worsen symptoms in schizophrenia patients on this drug. The interaction is specific to clozapine; other antipsychotics do not appear to share it. Glycine is contraindicated as a supplement in clozapine-treated patients.
- Severe kidney or liver disease. Patients with advanced renal or hepatic dysfunction should consult their nephrologist or hepatologist before supplemental glycine, because amino acid metabolism may be altered. The doses in question (3 g) are unlikely to be problematic but standard caution applies.
- Bipolar disorder. Glycine's NMDA coagonism is theoretically activating; rare anecdotal reports of mood elevation. Patients with bipolar disorder should monitor carefully and start at a low dose.
- Hereditary glycine encephalopathy (non-ketotic hyperglycinemia). A rare inborn error of metabolism in which glycine accumulates pathologically. These patients should obviously avoid supplemental glycine.
- Mild GI side effects. Doses above ~5 g taken at once can cause loose stool or mild stomach discomfort in some users. Splitting the dose or taking with a small amount of food resolves this.
- Sweet taste in beverages. Glycine is mildly sweet. People sensitive to taste-of-sweet at bedtime may prefer capsules over powder.
Key Research Papers
- Bannai M, Kawai N (2012). New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. Journal of Pharmacological Sciences. — PubMed
- Yamadera W, Inagawa K, Chiba S, et al. (2007). Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. Sleep and Biological Rhythms. — PubMed
- Inagawa K, Hiraoka T, Kohda T, Yamadera W, Takahashi M (2006). Subjective effects of glycine ingestion before bedtime on sleep quality. Sleep and Biological Rhythms. — PubMed
- Bannai M, Kawai N, Ono K, Nakahara K, Murakami N (2012). The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Frontiers in Neurology. — PubMed
- Kawai N, Sakai N, Okuro M, et al. (2015). The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. Neuropsychopharmacology. — PubMed
- Lopez-Corcuera B, Geerlings A, Aragon C (2001). Glycine neurotransmitter transporters: an update. Molecular Membrane Biology. — PubMed
- Lynch JW (2004). Molecular structure and function of the glycine receptor chloride channel. Physiological Reviews. — PubMed
- Heresco-Levy U, Javitt DC, Ermilov M, et al. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry. — PubMed
- Buchanan RW, Javitt DC, Marder SR, et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry. — PubMed
- Kruger T, Schiavi RC, Mandeli J, et al. (2003). Effects of acute glycine ingestion on cardiovascular response in healthy volunteers. Journal of Clinical Pharmacology. — PubMed
- Krystal AD, Benca RM, Kilduff TS (2013). Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. Journal of Clinical Psychiatry. — PubMed
- Razak MA, Begum PS, Viswanath B, Rajagopal S (2017). Multifarious beneficial effect of nonessential amino acid, glycine: a review. Oxidative Medicine and Cellular Longevity. — PubMed
- Hardeland R (2019). Aging, melatonin, and the pro- and anti-inflammatory networks. International Journal of Molecular Sciences. — PubMed
PubMed Topic Searches
- PubMed: glycine and sleep quality
- PubMed: glycine and thermoregulation
- PubMed: glycine receptor inhibitory neurotransmission
- PubMed: glycine NMDA coagonism in SCN
- PubMed: slow-wave sleep modulation